TNFα regulates cortisol metabolism in vivo in patients with inflammatory arthritis

Annals of the Rheumatic Diseases

Volumn 74, Issue 2, 2015, Pages 464-469

  Nanus, Dominika E ^a   Filer, Andrew D ^a,b   Hughes, Beverly ^a   Fisher, Benjamin A ^a,b   Taylor, Peter C ^c   Stewart, Paul M ^a   Buckley, Christopher D ^a,d   McInnes, Iain ^e   Cooper, Mark S ^a,f   Raza, Karim ^a,d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; C REACTIVE PROTEIN; ETANERCEPT; HYDROCORTISONE; INFLIXIMAB; STEROID 5ALPHA REDUCTASE; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID METABOLISM; DAS28; DISEASE ASSOCIATION; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; HUMAN; MALE; MASS FRAGMENTOGRAPHY; METABOLIC REGULATION; MIDDLE AGED; MOLECULAR PATHOLOGY; MULTICENTER STUDY; PROTEIN FUNCTION; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; URINALYSIS; AGED; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; METABOLISM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; ETANERCEPT; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROCORTISONE; IMMUNOGLOBULIN G; INFLIXIMAB; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921365830     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203926     Document Type: Article

References (23)

1. Buttgereit F, Burmester GR, Straub RH, et al. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011;63:1-9.
2. Saldanha C, Tougas G, Grace E. Evidence for anti-inflammatory effect of normal circulating plasma cortisol. Clin Exp Rheumatol 1986;4:365-6.
3. Raza K, Hardy R, Cooper MS. The 11beta-hydroxysteroid dehydrogenase enzymes - arbiters of the effects of glucocorticoids in synovium and bone. Rheumatology (Oxford) 2010;49:2016-23.
4. Tomlinson JW, Moore J, Cooper MS, et al. Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 2001;142:1982-9.
5. Cooper MS, Bujalska I, Rabbitt E, et al. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 2001;16:1037-44.
6. Hardy RS, Filer A, Cooper MS, et al. Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. Arthritis Res Ther 2006;8:R108.
7. Hardy RS, Rabbitt EH, Filer A, et al. Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis 2008;67:1204-10.
8. Arnett FC, Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
9. Palermo M, Shackleton CH, Mantero F, et al. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 1996;45:605-11.
10. Thieringer R, Le Grand CB, Carbin L, et al. 11 Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J Immunol 2001;167:30-5.
11. Schmidt M, Weidler C, Naumann H, et al. Reduced capacity for the reactivation of glucocorticoids in rheumatoid arthritis synovial cells: possible role of the sympathetic nervous system? Arthritis Rheum 2005;52:1711-20.
12. Kossintseva I, Wong S, Johnstone E, et al. Proinflammatory cytokines inhibit human placental 11beta-hydroxysteroid dehydrogenase type 2 activity through Ca2+ and camp pathways. Am J Physiol Endocrinol Metab 2006;290:E282-8.
13. Kostadinova RM, Nawrocki AR, Frey FJ, et al. Tumor necrosis factor alpha and phorbol 12-myristate-13-acetate down-regulate human 11beta-hydroxysteroid dehydrogenase type 2 through p50/p50 NF-kappaB Homodimers and Egr-1. FASEB J 2005;19:650-2.
14. Schett G, Hayer S, Zwerina J, et al. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005;1:47-54.
15. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
16. Hardy R, Juarez M, Naylor A, et al. Synovial DKK1 expression is regulated by local glucocorticoid metabolism in inflammatory arthritis. Arthritis Res Ther 2012;14:R226.
17. Angel K, Provan SA, Fagerhol MK, et al. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012;25:644-50.
18. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-18.
19. Wijbrandts CA, Klaasen R, Dijkgraaf MG, et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 2009;68:373-6.
20. Seriolo B, Paolino S, Sulli A, et al. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006;1069:420-7.
21. Schmidt M, Weidler C, Naumann H, et al. Androgen conversion in osteoarthritis and rheumatoid arthritis synoviocytes - androstenedione and testosterone inhibit estrogen formation and favor production of more potent 5alpha-reduced androgens. Arthritis Res Ther 2005;7:R938-48.
22. Boonen E, Vervenne H, Meersseman P, et al. Reduced cortisol metabolism during critical illness. N Engl J Med 2013;368:1477-88.
23. Palermo M, Marazzi MG, Hughes BA, et al. Human delta4-3-oxosteroid 5beta-reductase (AKR1D1) deficiency and steroid metabolism. Steroids 2008;73:417-23.